Experience with cyclosporine in endogenous uveitis posterior
Experience with cyclosporine in endogenous uveitis posterior
复制标题
DOI：
10.1016/j.transproceed.2004.01.003
复制
发表时间：
2004-03-01
影响因子：
0.9
通讯作者：
van Hagen, PM
中科院分区：
文献类型：
--
作者：
Hesselink, DA;Baarsma, GS;van Hagen, PM
环孢素（CsA）治疗已大大改善了内源性后葡萄膜炎（EPU）患者的视力预后。然而，CsA的治疗益处部分被其许多副作用所抵消，最明显的是肾毒性和高血压。低剂量CsA方案降低了毒性，但不能完全消除这个问题。新的治疗方法，例如抗肿瘤坏死因子a治疗或使用他克莫司、西罗莫司和白细胞介素-2受体抗体等药物进行免疫抑制，目前正在评估中。希望这些策略将进一步降低EPU的发病率，并最大限度地减少与传统治疗相关的不良反应。
Treatment with cyclosporine (CsA) has considerably improved the visual prognosis of patients suffering from endogenous posterior uveitis (EPU). However, the therapeutic benefits of CsA are partially outweighed by its many side effects, most notably nephrotoxicity and hypertension. Low-dose CsA regimens have reduced toxicity but have not been able to completely eliminate this problem. New therapeutic approaches, such as antitumor necrosis factor a treatment or immunosuppression with drugs including tacrolimus, sirolimus, and interleukin-2 receptor antibodies, are currently under evaluation. Hopefully such strategies will further reduce the morbidity of EPU and minimize the adverse effects associated with conventional therapies.